Cargando…

Advances in efficacy prediction and monitoring of neoadjuvant immunotherapy for non-small cell lung cancer

The use of immune checkpoint inhibitors (ICIs) has become mainstream in the treatment of non-small cell lung cancer (NSCLC). The idea of harnessing the immune system to fight cancer is fast developing. Neoadjuvant treatment in NSCLC is undergoing unprecedented change. Chemo-immunotherapy combination...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yunzhen, Huang, Sha, Feng, Xiangwei, Xu, Wangjue, Luo, Raojun, Zhu, Ziyi, Zeng, Qingxin, He, Zhengfu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10229830/ https://www.ncbi.nlm.nih.gov/pubmed/37265800 http://dx.doi.org/10.3389/fonc.2023.1145128

Ejemplares similares

Efficacy and safety evaluation of neoadjuvant immunotherapy plus chemotherapy for resectable non–small cell lung cancer in real world
por: Fang, Min, et al.
Publicado: (2023)

Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers
por: Wu, Xinyu, et al.
Publicado: (2023)

Neoadjuvant immunotherapy and neoadjuvant chemotherapy in resectable non-small cell lung cancer: A systematic review and single-arm meta-analysis
por: Wang, He, et al.
Publicado: (2022)

Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in locally advanced esophageal cancer: A meta-analysis
por: Wang, Jincheng, et al.
Publicado: (2022)

Comparative Efficacy and Safety of Immunotherapy Alone and in Combination With Chemotherapy for Advanced Non-small Cell Lung Cancer
por: Wang, Xue, et al.
Publicado: (2021)

Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non-Small Cell Lung Cancer
por: Xiong, Qi, et al.
Publicado: (2021)

Neoadjuvant and Adjuvant Immunotherapy: Opening New Horizons for Patients With Early-Stage Non-small Cell Lung Cancer
por: Bai, Rilan, et al.
Publicado: (2020)

A comparison of two methods of lymph node dissection along the left recurrent laryngeal nerve in McKeown minimally invasive esophagectomy
por: Zhu, Ziyi, et al.
Publicado: (2023)

Association of early immune-related adverse events with treatment efficacy of neoadjuvant Toripalimab in resectable advanced non-small cell lung cancer
por: Tao, Ye, et al.
Publicado: (2023)

CT-based radiomics in predicting pathological response in non-small cell lung cancer patients receiving neoadjuvant immunotherapy
por: Lin, Qian, et al.
Publicado: (2022)

Neoadjuvant immunotherapy combined with chemotherapy significantly improved patients’ overall survival when compared with neoadjuvant chemotherapy in non-small cell lung cancer: A cohort study
por: Dai, Fuqiang, et al.
Publicado: (2022)

Before or After: Evolving Neoadjuvant Approaches to Locally Advanced Non-Small Cell Lung Cancer
por: Lewis, Jennifer, et al.
Publicado: (2018)

Different pathological response and histological features following neoadjuvant chemotherapy or chemo-immunotherapy in resected non-small cell lung cancer
por: Alì, Greta, et al.
Publicado: (2023)

Imaging Biomarkers to Predict and Evaluate the Effectiveness of Immunotherapy in Advanced Non-Small-Cell Lung Cancer
por: Liu, Ying, et al.
Publicado: (2021)

Current Evidence of the Efficacy and Safety of Neoadjuvant EGFR-TKIs for Patients With Non-small Cell Lung Cancer
por: Shi, Xiaoshun, et al.
Publicado: (2021)

Expression of Microtubule-Associated Proteins in Relation to Prognosis and Efficacy of Immunotherapy in Non-Small Cell Lung Cancer
por: Luo, Jieyan, et al.
Publicado: (2021)

Antiangiogenesis for Advanced Non-Small-Cell Lung Cancer in the Era of Immunotherapy and Personalized Medicine
por: Tabchi, Samer, et al.
Publicado: (2017)

Advances in Imaging in Evaluating the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer
por: Kong, Xianshu, et al.
Publicado: (2022)

Surgical Outcomes After Neoadjuvant Chemoimmunotherapy for Resectable Non-Small Cell Lung Cancer
por: Hu, Yan, et al.
Publicado: (2021)

Research Progress on the Microenvironment and Immunotherapy of Advanced Non-Small Cell Lung Cancer With Liver Metastases
por: Fang, Yujia, et al.
Publicado: (2022)

Immunotherapy progress and clinical strategy of unresectable locally advanced non-small cell lung cancer
por: Zhang, Xiaofei, et al.
Publicado: (2023)

Metabolomics profiling in prediction of chemo-immunotherapy efficiency in advanced non-small cell lung cancer
por: Mei, Lihong, et al.
Publicado: (2023)

Toxicities of Immunotherapy for Small Cell Lung Cancer
por: Fu, Yang, et al.
Publicado: (2021)

Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma
por: Ho, Joel, et al.
Publicado: (2022)

Neoadjuvant Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer
por: Sher, David J.
Publicado: (2017)

Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer
por: Peng, Yurong, et al.
Publicado: (2023)

Transferred by exosomes-derived MiR-19b-3p targets PTEN to regulate esophageal cancer cell apoptosis, migration and invasion
por: Zeng, Qingxin, et al.
Publicado: (2020)

Neoadjuvant Therapy for Locally Advanced Esophageal Cancers
por: Huang, Runkai, et al.
Publicado: (2022)

Current and novel therapeutic strategies for optimizing immunotherapy outcomes in advanced non-small cell lung cancer
por: Martin, Claudio, et al.
Publicado: (2022)

Checkpoint inhibitors as dual immunotherapy in advanced non-small cell lung cancer: a meta-analysis
por: Alifu, Muyesar, et al.
Publicado: (2023)

Immunotherapy for Head and Neck Cancer: A Paradigm Shift From Induction Chemotherapy to Neoadjuvant Immunotherapy
por: Shibata, Hirofumi, et al.
Publicado: (2021)

Safety and feasibility of robotic-assisted thoracic surgery after neoadjuvant chemoimmunotherapy in non-small cell lung cancer
por: Zeng, Jun, et al.
Publicado: (2023)

Corrigendum: Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer
por: Peng, Yurong, et al.
Publicado: (2023)

Pre-Immunotherapy Contrast-Enhanced CT Texture-Based Classification: A Useful Approach to Non-Small Cell Lung Cancer Immunotherapy Efficacy Prediction
por: Shen, Leilei, et al.
Publicado: (2021)

Progression Patterns, Treatment, and Prognosis Beyond Resistance of Responders to Immunotherapy in Advanced Non-Small Cell Lung Cancer
por: Xu, Yanjun, et al.
Publicado: (2021)

Cell adhesion molecules and immunotherapy in advanced non-small cell lung cancer: Current process and potential application
por: Yang, Hongjian, et al.
Publicado: (2023)

Neoadjuvant therapy for locally advanced non-small cell lung cancer: TKIs or immunotherapy?
por: Zhang, Zhenyang, et al.
Publicado: (2020)

Efficacy of Combination Chemo-Immunotherapy as a First-Line Treatment for Advanced Non-Small-Cell Lung Cancer Patients With HER2 Alterations: A Case Series
por: Zhao, Shuang, et al.
Publicado: (2021)

Indirect comparison between immunotherapy alone and immunotherapy plus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a systematic review
por: Li, Lingling, et al.
Publicado: (2020)

First-Line Chemo-Immunotherapy for Extensive-Stage Small-Cell Lung Cancer: A United States-Based Cost-Effectiveness Analysis
por: Liu, Qiao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9hq3g1n5bk3ahs9fc59vhdt052